Il Trattamento Chemioterapico Del Carcinoma Prostatico: Ruolo Potenziale Del Docetaxel

Abstract

Get full access to this article

View all access options for this article.

References

Greenlee

R.T.

, Murray

, Bolden

: Cancer statistics, 1999.

Goktas

, Crawford

: Optimal hormonal therapy in advanced prostatic carcinoma. Sem Oncol 26: 162–173, 1999.

Ripple

G.H.

, Wilding

: Drug development in prostate carcinoma. Sem Oncol 26: 217–226, 1999.

Eisemberger

M.A.

, Abrams

J.S.

: Chemotherapy for prostatic carcinoma. Sem Urol 6: 303–310, 1988.

Yagoda

A.Q.

, Petrylak

: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 371: 1098–1109, 1993.

Seidman

A.D.

, Scher

H.I.

, Petrylak

: Effect of estramustine and vinblastine. Use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J Urol 147: 931–934, 1992.

Hudes

, Roth

, Loehrer

: Phase III trial of vinblastine vs vinblastine plus estramustine phosphate for metastatic hormone refractory prostate cancer (HRPC). Proc ASCO 16:316a, 1997 (abstr).

Pienta

K.J.

, Redman

, Hussain

: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12: 2005–2012, 1994.

Pienta

H.J.

, Redman

, Bandekar

: A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50: 401–407 1997.

10.

Dimoppoulos

M.A.

, Panopoulos

, Bamia

: Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 50: 754–758, 1997.

11.

Tannock

I.F.

, Osoba

, Stockier

M.R.

: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end point. J Clin Oncol 14: 1756–1764, 1996.

12.

Kantoff

P.W.

, Halabi

, Conaway

: Hidrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer. Results of the CALGB 9182 study. J Clin Oncol 17: 2506–2513, 1999.

13.

Roth

B.J.

, Yeap

B.Y.

, Wilding

Taxol in advanced hormone-refractory prostate carcinoma phase II trial of the Eastern Cooperative Oncology Group.

Cancer 72: 2457–2460, 1993.

14.

Hudes

G.R.

, Nathan

, Khater

: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphase in metastatic hormone-refractory prostate cancer. J Clin Oncol 15: 3156–3163, 1997.

15.

Kreiss

, Budman

D.R.

, Fetten

: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Cancer 10: 33–38, 1999.

16.

Petrylac

D.P.

, Macarthur

R.B.

, O'Conner

: Phase I trial of docetaxel with estramustine in androgen-indipendent prostate cancer. J Clin Oncol 17: 958–967, 1999.